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Targeting adhesion to the vascular
niche to improve therapy for acute
myeloid leukemia
Myriam L. R. Haltalli 1,2,3 & Cristina Lo Celso 1,2✉
Niche hijack by malignant cells is considered to be a prominent cause of disease
relapse. Barbier and colleagues uncover (E)-selectin as a novel mediator of
malignant cell survival and regeneration which, upon blockade, has the potential
to significantly improve therapeutic outcomes.
Not-so-welcome to the neighborhood
Hematopoietic stem cells (HSCs) sit at the top of the hematological hierarchy as multipotent
cells with the capacity to self-renew and give rise to various progenitor populations, which
maintain the production of short-lived mature lineages (including blood cells) throughout life.
They reside within the bone marrow (BM), within specialized niches that facilitate their survival
and regulate their function via local interactions with diverse stromal and hematopoietic cells. It
is widely accepted that spatially distinct niches exist to support HSCs with a range of differ-
entiation biases and quiescence states. These are broadly split into the central BM niche, located
in the deeper BM and rich in sinusoid capillaries, and the endosteal niche, in close proximity to
the bone inner surface and rich in arterioles and transitional vessels that feed into the sinusoidal
network1. In both locations, HSCs reside in perivascular niches where endothelial cells (ECs) and
their associated mesenchymal stem cells critically maintain and regulate them2.
Hematological malignancies, such as acute myeloid leukemia (AML), tend to arise from the
expansion of transformed hematopoietic stem and progenitor cells (HSPCs) with subclonal
genotypes, resulting in refractory clones that are able to resist chemotherapy and ultimately lead
to the relapse of disease. Leukemia stem cells (LSCs) share many features with healthy HSCs,
which has led to the hypothesis that LSCs similarly reside in, and depend on, specific BM
“neighborhoods” that support their expansion and survival3,4. There is a growing need for novel
therapies to reduce malignancy-associated morbidity and mortality and, due to the fact that
many mechanisms of immune evasion and chemoresistance are partly dependant on it, the BM
niche represents a unique target to improve treatment outcomes5. The recent work by Barbier
and colleagues6 is therefore timely as it reveals, using AML as a model, a new cell-extrinsic
niche-based pathway that directly mediates therapy resistance. The authors propose a method
with the potential to improve AML treatment efficacy by targeting the vascular niche.
Holding on tight
Endothelial (E)-selectins are cell adhesion molecules expressed in the vascular niche, which have
well-characterized roles in leukocyte homing. E-selectin is constitutively expressed on BM
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endothelium, aiding the homing and engraftment of circulating
HSPCs that possess the necessary counter-receptors. Previous
work had demonstrated that adhesion to E-selectin promotes the
proliferation of HSCs, directly triggers their activation and
induces lineage commitment7. Interestingly, based on earlier
observations of E-selectin expression in BM areas where leukemia
cells home8, the hypothesis arose that LSCs may be protected
from the effects of chemotherapy through their anchorage in
niches enriched in its expression. The work from Winkler et al.
uncovered an unexpected additional role for this adhesion
molecule as a therapeutic target when its inhibition induced HSC
chemoresistance and radioresistance. Overall, their findings
raised the question whether specific binding of tumor cells with
endothelium expressing E-selectin might regulate tumor growth
and proliferation7. Barbier et al. address this question and show
that, in the context of disease, interaction with E-selectin plays a
direct role in promoting malignant cells’ survival in the BM, a
textbook example of niche hijack.
Inflammation is a hallmark of cancer and we have previously
hypothesized that it is a key player in driving remodeling of the
BM niche during leukemia9. E-selectin is expressed by ECs at the
leading edge of solid tumors and at pre-metastatic sites, which are
also highly inflammatory environments10,11. Barbier et al.
demonstrate that the inflammation generated by AML in the BM
directly drives the increased levels of E-selectin on BM ECs of
leukemic mice. This resulted in the postulation that the specific
upregulation on tumor-associated vasculature may be less
involved in the homing of AML cells, but more so as a factor
directly contributing to their survival and regeneration by creat-
ing a protective niche for LSCs to hold on to, thus promoting
therapy resistance.
A novel target for improved therapy
While there is an ever-increasing number of targeted therapies to
treat leukemia, patient outcome remains poor, thus there is an
urgent need to develop new strategies. Over the past few years,
with the advance of increasingly sophisticated technologies to
study the BM microenvironment, we have gained fascinating
insight into this tissue. We can now appreciate that it is a complex
and dynamic entity that actively interacts with healthy hemato-
poietic cells, as well as their malignant counterparts, playing an
important role in directing their fates. Our knowledge of how
leukemia cells co-opt and alter BM niches offers many oppor-
tunities for therapeutic exploitation, and more targeted inter-
ventions of novel pathways to restore healthy hematopoiesis and
limit disease relapse.
By elegantly demonstrating that the leukemic blasts most likely
to survive chemotherapy were those characterized by higher E-
selectin binding potential, Barbier and colleagues suggested that
these cells were the main contributors to disease relapse. To test
the role of E-selectin in supporting malignant cells, they sought to
understand the outcome if this adhesion molecule was absent in
the BM (using an E-selectin gene knock-out mouse model) or
blocked therapeutically. E-selectin can be inhibited by adminis-
tering a selective small molecule antagonist called GMI-1271 (also
known as uproleselan). It has been shown that this treatment
effectively displaces chronic myeloid leukemia (CML) cells from
the BM endothelium, promoting cell cycle progression and
downregulating the expression of the E-selectin ligand CD44—
thus reinforcing the reduced adhesion of CML cells to the BM
endothelium12. Using an innovative method, the authors inves-
tigated whether functional LSCs were amongst those protected by
E-selectin-mediated interactions in the vascular niche. They
developed a quantitative in vivo LSC chemosensitivity assay,
based on the principle of limiting dilution transplants widely used
for enumerating HSCs. By comparing the number of persisting
LSCs in recipients of BM cells from chemotherapy-treated, E-
selectin gene-deleted, or GMI-1271-treated wild-type mice, they
demonstrated that the deletion or blockade of E-selectin drasti-
cally reduced LSC survival. Therefore, E-selectin mediates sig-
nificant intracellular pro-survival signaling for LSCs, and this
unique characteristic was not replicated by other adhesion
molecules and chemokines involved in BM retention.
Up until now, combinations of chemotherapy with approaches
that target mainly AML-intrinsic mechanisms have been pro-
posed13, including the use of CXCR4 antagonists14 and anti-
inflammatory therapies15. With this work, the authors bring to
light the fact that cell-extrinsic targets could prove hugely valu-
able in future phases of therapy development. By administering
GMI-1271 alongside a standard chemotherapy regime in leu-
kemic mice, Barbier et al. were able to double the duration of
mouse survival over chemotherapy alone. Endogenous, healthy,
HSPC populations exhibited strikingly different responses when
compared to AML blasts, suggesting that this treatment strategy
protects those populations in the BM. These intriguing data
demonstrate that therapeutic blocking of this vascular niche-
mediated survival pathway could complement conventional AML
treatment regimens to improve efficacy and extend overall
survival.
Future directions and clinical impact
We must harness the progress made so far in creating a detailed
map of the BM microenvironment with all of its structures and
components at steady state, in order to keep elucidating the
underlying mechanisms of disease-mediated niche hijack. The
number of clinical trials arising from a deeper understanding of
the HSC niche is bound to increase. Based on the work presented
by Barbier and colleagues, a phase I/II clinical trial is already in
progress to evaluate the use of GMI-1271 alongside standard
therapy in relapsed/refractory adult AML (NCT02306291). So far,
they have shown greater rates of clinical remission and extended
median patient survival, which is consistent with the findings
in vivo presented by the authors. The future of these “nicho-
therapies”16 to facilitate chemotherapy looks extremely promising
given the rise in demand for new agents with good tolerance in a
broad range of AML patients, increased efficacy and, most
importantly, the ability to limit disease relapse. The work pre-
sented here provides hope that innovative methods of targeting
malignant BM niches could be the key to making AML a treatable
disease.
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